Drug Profile
Olaratumab - Eli Lilly and Company
Alternative Names: IMC-3G3; Lartruvo; LY 3012207Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer Eli Lilly and Company; Institute for Clinical Oncological Research; Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Platelet derived growth factor alpha receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Soft tissue sarcoma
- Phase I/II Pancreatic cancer
- No development reported Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
Most Recent Events
- 28 Apr 2023 Phase-I development in Soft tissue sarcoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in USA, Denmark, Belgium and France (IV, Infusion) (NCT03126591)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (IV, Infusion)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Denmark (IV, Infusion)